Benjamin Hohl - 12 Feb 2026 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Signature
/s/ Benjamin Hohl
Issuer symbol
ELVN
Transactions as of
12 Feb 2026
Net transactions value
$0
Form type
4
Filing time
17 Feb 2026, 19:49:32 UTC
Previous filing
23 Dec 2025
Next filing
10 Mar 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hohl Benjamin CHIEF FINANCIAL OFFICER C/O ENLIVEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER /s/ Benjamin Hohl 17 Feb 2026 0001882764

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELVN Common Stock Award $0 +25,000 +69% $0.000000 61,000 12 Feb 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELVN Stock Option (right to buy) Award $0 +150,000 $0.000000 150,000 12 Feb 2026 Common Stock 150,000 $27.16 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date.
F2 Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F3 1/4th of the shares subject to the option will vest on February 12, 2027 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.